Cash, cash equivalents, and marketable securities were $86.7 million as of June 30, 2024, compared to $101.6 million as of March 31, 2024. The Company expects its cash, cash equivalents and marketable securities, together with the $40 million gross proceeds received from Sanofi in July, will fund its operational plans into 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
- Vigil Neuroscience publishes new data on CSF1R gene variants
- Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer’s Association International Conference (AAIC)
- Vigil Neuroscience’s Promising Phase 1 Trial and Alzheimer’s Focus
- Vigil Neuroscience announces interim data from ongoing Phase 1 trial on VG-3927